Improved sensitivity in BRAFV600E detection in combined tissue and extracellular vesicles-based liquid biopsy in melanoma.

To the editor, cutaneous melanoma in its early stages is a curable disease by surgery of skin lesions. However, intermediate stages display variable outcomes. BRAF V600 mutations are the most frequent alterations in melanoma ocurring in 35-50% of patients ( Luke et al., 2017) and remain informative for guiding first-line treatment election ( Robert et al., 2019).

Description

This study was approved by the institutional ethical review board (CEIC) of Hospital 12 de Octubre (Madrid, Spain) and institutional review board information is04.625 version September 26th2018 on Act 20/18 dated by November 13th2018. Written informed consent was obtained from all participants. Conflict of Interest StatementJohan Skog has patents for exosome-based technologies and is an employee and shareholder of Bio-techne. J. Aquiles Sanchez is an employee of Bio-techne. Lisa Meyer, Daniel Enderle and Mikkel Noerholm are former employees of Bio-techne. Authors declare no additional conflicts of interes

Keywords

BRAF Melanoma Biomarkers Oncology Tumors markers Cancer

Bibliographic citation

J Invest Dermatol. 2023 Feb 15;S0022-202X(23)00091-X.

Collections

Grupos de investigación

Publisher version

https://doi.org/10.1016/j.jid.2023.01.025.

Document type

preprint

Full item page

Publication:
Improved sensitivity in BRAFV600E detection in combined tissue and extracellular vesicles-based liquid biopsy in melanoma.